Program
MRNA-1083
A development code. Also written as “mRNA-1083”, “mRNA-1083.1” and “mRNA-1083.2”.
Its studies are mostly in Influenza, Human · COVID-19, led by Moderna.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Moderna | 50 open or running | phase 3since Oct 18, 2023 | Apr 24, 2023 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 24, 2023First study: phase 2 study in Influenza, HumanFirst studyNCT05827926 · 1,758 enrolled · United States
- Oct 18, 2023Phase 3 study in Influenza, HumanNCT06097273 · 8,061 enrolled · United States
- Jul 12, 2024Phase 2 study in Influenza, HumanNCT06508320 · 931 enrolled · United States, Canada
- Nov 15, 2024Phase 3 study in COVID-19NCT06694389 · 2,457 enrolled · Japan, South Korea, Taiwan
- Mar 5, 2025Phase 2 study in Influenza, HumanNCT06864143 · 1,320 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06864143Influenza, Human · United States | 2 | Completed | Oct 13, 2025 | 1,320 |
| NCT06694389COVID-19 · Japan, South Korea, Taiwan | 3 | Completed | Nov 17, 2025 | 2,457 |
| NCT06508320Influenza, Human · United States, Canada | 2 | Completed | Sep 25, 2025 | 931 |
| NCT06097273Influenza, Human · United States | 3 | Completed | May 28, 2024 | 8,061 |
| NCT05827926Influenza, Human · United States | 2 | Completed | Dec 3, 2024 | 1,758 |
How it is read
Names in the registry
- “mRNA-1083”, 4 entries
- “mRNA-1083.1”, 1 entry
- “mRNA-1083.2”, 1 entry
- “mRNA-1083.3”, 1 entry
- “mRNA-1083 Composition 1 Dose A Lot A”, 1 entry
Codes read as this program: MRNA1083.
Conditions, from the studies’ own filings
- Influenza, Human, 4 studies
- COVID-19, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.